Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Long-Term Debt Repayments (2016 - 2025)

Fortress Biotech (FBIO) has 12 years of Long-Term Debt Repayments data on record, last reported at $625000.0 in Q1 2025.

  • For Q1 2025, Long-Term Debt Repayments changed N/A year-over-year to $625000.0; the TTM value through Sep 2025 reached $1.2 million, up 106.65%, while the annual FY2024 figure was $1.2 million, 95.96% down from the prior year.
  • Long-Term Debt Repayments reached $625000.0 in Q1 2025 per FBIO's latest filing, roughly flat from $625000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $27.9 million in Q1 2023 and bottomed at -$19.4 million in Q4 2023.
  • Average Long-Term Debt Repayments over 5 years is $3.6 million, with a median of $1.0 million recorded in 2022.
  • Peak YoY movement for Long-Term Debt Repayments: plummeted 137.74% in 2022, then skyrocketed 3341.87% in 2023.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $5.1 million in 2021, then plummeted by 138.83% to -$2.0 million in 2022, then tumbled by 871.35% to -$19.4 million in 2023, then skyrocketed by 103.22% to $625000.0 in 2024, then changed by 0.0% to $625000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $625000.0 in Q1 2025, $625000.0 in Q4 2024, and $625000.0 in Q3 2024.